logo
Plus   Neg
Share
Email

Amarin Corp. (AMRN) Has Soared To A New High On Study Results

Amarin Corp. (AMRN) announced Monday morning that the Vascepa cardiovascular or CV outcomes trial, REDUCE-IT, met its primary endpoint.

Amarin has gapped open dramatically higher this morning and is now up 7.90 at $10.89 on the highest volume of the year. The stock has soared to a new high for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

RELATED NEWS
Follow RTT
>